Pharma manufacturing news in brief
pharmafile | March 8, 2011 | News story | Manufacturing and Production | Bristol-Myers Squibb, CSM GlobalPharma, Carbogen Amcis, Quotient Clinical, SCM Pharma, WuXi PharmaTech
Facility updates from Bristol-Myers Squibb, WuXi PharmaTech, Quotient Clinical, CSM GlobalPharma and SCM Pharma, plus a reorganisation of Carbogen Amcis’ Swiss facilities.
Bristol-Myers Squibb has formed a partnership with Chinese contract service company WuXi PharmaTech that will centre on conduct of stability testing of new small-molecule medicines. As part of the agreement WuXi will construct a 25,000 sq.ft. facility in Shanghai to store and test samples to see how they are affected by factors such as temperature, humidity and light, and to establish product shelf lives.
Drug development services provider Quotient Clinical has completed an expansion of its GMP-grade manufacturing suite in Nottingham, UK, for oral, inhaled and parenteral products. The suite has doubled in size and will be used to serve customers for Quotient’s RapidFACT (Rapid Formulation and Clinical Testing) service, which it claims cuts the development time for new drug formulations by 50-60%, while using 90% less active pharmaceutical ingredient (API).
Cadila Pharmaceutical subsidiary CSM GlobalPharma will invest $64 million in a manufacturing facility in Rwanda that will make a wide range of finished medicines as well as active pharmaceutical ingredients, reports AllAfrica.com. The aim is to make Rwanda self-sufficient in many essential medicines and reduce its high rate of reliance on imported drugs. The plant is due to be operational within two years.
SCM Pharma of the UK has expanded its high-potency active pharmaceutical ingredient (HPAPI) manufacturing capacity with the investment of £500,000 ($810,000) in a new cleanroom at its facility in Northumberland. The move follows increased demand for potent fill/finish services at SCM Pharma for both clinical trial and commercial supply projects in addition to meeting the scaling-up requirements of other existing pharmaceutical clients, said the firm.
Swiss API supplier and process development specialist Carbogen Amcis is planning to restructure its units in Bubendorf, Aarau and Hunzenschwil “on the grounds of inadequate profitability”. Around 60 staff will be made redundant as a result of the revamp. After the restructuring, Aarau will focus more strongly on development services, Hunzenschwil will concentrate on pilot production of early phase projects, and large-volume production will continue at Bubendorf.
Phil Taylor
Related Content
NICE approves first treatment for obstructive HCM for NHS use
The National Institute for Health and Care Excellence (NICE) has announced that it has approved …
Bristol Myers Squibb psoriasis drug shows positive Phase III results
Bristol Myers Squibb’s investigational deucravacitinib drug, for the treatment of moderate-to-severe plaque psoriasis, has shown …
Molecular Templates signs cancer deal with BMS worth up to $1.3bn
Molecular Templates and Bristol Myers Squibb have entered into a worldwide strategic research collaboration worth …
